7 March 2019

PDMR Dealing

LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 6, 2019, Dr. David Ebsworth, Chairman of the Company, purchased 26,300 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 56.30 pence per Ordinary Share and a total purchase price of £14,806.90 Following the acquisition, Dr. Ebsworth will have an interest in the Company of 217,887 Ordinary Shares, representing 0.21% of the Company’s issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name David Ebsworth
 
2 Reason for the notification
a) Position/status Chairman
 
b) Initial notification/Amendment Initial notification
 
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b)
 
LEI
 
213800EVI6O6J3TIAL06
 

 

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
 
Description of the financial instrument, type of instrument

Identification code
Ordinary Shares of 5 pence each

GB00BYW2KH80
b)
 
Nature of the transaction
 
David Ebsworth purchased 26,300 Ordinary Shares
 
       
c) Price(s) and volume(s) Price(s) Volume(s)
    56.30 pence per Ordinary Share 26,300 Ordinary Shares
d) Aggregated information

- Aggregated volume

- Price
N/A
e) Date of the transaction 6 March 2019
f) Place of the transaction London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

Stifel Nicolaus Europe Ltd (Nominated Adviser and UK Broker)
Jonathan Senior / Stewart Wallace
Tel: +44 (0)20 7710 7600

 

 

FTI Consulting
Simon Conway / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us